The maker of Botox, breast implants and a variety of eye care products said Q3 EPS rose 15% to $1.06, beating views by 2 cents. Sales rose 6.4% to $1.41 bil, under views. Product sales rose 9.4%, pharmaceuticals gained 11.4% and medical devices shrank 0.3%. For Q4, Allergan (AGN) guided EPS in the range of $1.18-$1.20. Analysts are expecting $1.20.